Mineralys Therapeutics awards stock options to boost hypertension drug development

Mineralys Therapeutics, a biopharmaceutical company based in Radnor, Pennsylvania, has granted a stock option award to a newly hired non-executive employee. The inducement covers 146,000 shares and aligns with the firm's focus on developing treatments for hypertension and related conditions. Founded in 2025 by Catalys Pacific, the company is advancing its first product candidate, lorundrostat, a novel oral medication for blood pressure control.

The stock option award was issued under Mineralys' 2025 Employment Inducement Incentive Award Plan. Vesting will occur over four years, with 25% becoming available after the first year and the remaining shares vesting monthly thereafter.

Mineralys specialises in medicines targeting hypertension and associated health complications. Its lead drug, lorundrostat, is an orally administered inhibitor designed to selectively block aldosterone synthase. This mechanism aims to regulate normal blood pressure more effectively than existing treatments.

The company has not disclosed how many non-executive employees it has hired since its launch in 2025. However, the latest award signals ongoing expansion as it progresses its clinical-stage pipeline.

The inducement award reflects Mineralys' strategy to attract talent while advancing its hypertension drug programme. Lorundrostat remains the primary focus as the company works toward clinical milestones. Further details on hiring trends or additional awards have not been made public.